Home Cart Sign in  
Chemical Structure| 1137868-52-0 Chemical Structure| 1137868-52-0

Structure of TAK-960
CAS No.: 1137868-52-0

Chemical Structure| 1137868-52-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TAK-960 is an investigational, orally bioavailable, potent, and selective PLK1 inhibitor (IC50=1.5 nM) that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TAK-960

CAS No. :1137868-52-0
Formula : C27H34F3N7O3
M.W : 561.60
SMILES Code : O=C(NC1CCN(C)CC1)C2=CC(OC)=C(NC3=NC=C(N4C)C(N(C5CCCC5)CC(F)(F)C4=O)=N3)C=C2F
MDL No. :MFCD22420821
InChI Key :GWRSATNRNFYMDI-UHFFFAOYSA-N
Pubchem ID :53357478

Safety of TAK-960

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT116 cells 8 nM 12 hours Induced G2/M phase cell cycle arrest, increased sensitivity to radiation Sci Rep. 2015 Oct 27;5:15666
H1299 cells 8 nM 12 hours Induced G2/M phase cell cycle arrest, increased sensitivity to radiation Sci Rep. 2015 Oct 27;5:15666
HeLa cells 8 nM 12 hours Induced G2/M phase cell cycle arrest, increased sensitivity to radiation Sci Rep. 2015 Oct 27;5:15666
LS141 cells 50 nM 48 hours Stayed at 4N with mild apoptosis Cell Cycle. 2015;14(19):3101-11
CHP100 cells 50 nM 48 hours Induced apoptosis with Mcl-1 downregulation Cell Cycle. 2015;14(19):3101-11
MPNST cells 50 nM 48 hours Induced polyploidy without apoptosis Cell Cycle. 2015;14(19):3101-11
COLO678 (KRASG12D/PIK3CAWT) 0.1, 0.5, 1, 2 µM 72 hours To evaluate the effect of TAK-960 on colony formation, showing dose-dependent reduction in colony formation, but with weaker effects. BMC Cancer. 2018 Feb 5;18(1):136
DLD1 (KRASG13D/PIK3CAD549N E545K) 0.1, 0.5, 1, 2 µM 72 hours To evaluate the effect of TAK-960 on colony formation, showing dose-dependent reduction in colony formation, but with weaker effects. BMC Cancer. 2018 Feb 5;18(1):136
HCT116 (KRASG13D/PIK3CAH1047R) 0.1, 0.5, 1, 2 µM 72 hours To evaluate the effect of TAK-960 on colony formation, showing dose-dependent reduction in colony formation. BMC Cancer. 2018 Feb 5;18(1):136
WIDR (KRASWT/BRAFV600E/PIK3CAP449T) 0.1, 0.5, 1, 2 µM 72 hours To evaluate the effect of TAK-960 on colony formation, showing dose-dependent reduction in colony formation. BMC Cancer. 2018 Feb 5;18(1):136

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female athymic nude mice 18 colorectal cancer patient-derived xenograft models Oral gavage 10 mg/kg Once daily for at least 28 days To assess the antitumor activity of TAK-960 in vivo, showing 6 out of 18 PDX models were sensitive to TAK-960 (TGII<20). BMC Cancer. 2018 Feb 5;18(1):136
Nude mice HeLa tumor xenograft model Oral 10 mg/kg Single dose, radiation performed 24 hours later Increased tumor cell sensitivity to radiation, significantly delayed tumor growth Sci Rep. 2015 Oct 27;5:15666
Nude mice MPNST and CHP100 xenograft models Oral 10 mg/kg Once daily for 3 weeks CHP100 xenografts showed stronger tumor growth inhibition and apoptosis, MPNST xenografts showed polyploidy Cell Cycle. 2015;14(19):3101-11

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01179399 Advanced Nonhematological Mali... More >>gnancies Less << PHASE1 TERMINATED 2025-01-13 South Texas Accelerated Resear... More >>ch Therapeutics (START), San Antonio, Texas, 78229, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.90mL

1.78mL

0.89mL

17.81mL

3.56mL

1.78mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories